Does CNS pay a dividend and is it safe?

Cohen & Steers Inc (CNS) offers a 3.39% cash dividend yield ($2.52 annualized) and 3.99% total shareholder yield including buybacks. Roarable rates its payout coverage as ELEVATED PAYOUT WATCH.

Stock Ratings / Financials / CNS / dividends

LAZ (59) FHI (74) AAMI (50) HTGC (42) ⌘ Pro Terminal →

Cohen & Steers Inc (CNS) Dividend Safety Gauge & 10-Year DRIP Compounder

$74.38 +2.62% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $74.59

Cohen & Steers Inc (CNS) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $3.73B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CNS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CNS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Cohen & Steers Inc (NYSE: CNS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $74.38 (+2.62% 1D, market cap $3.73B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 7/20. Across 1097 tracked Financials issuers, CNS ranks #840 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CNS compare to LAZ and FHI in the Financials sector?

▼

Within the Financials sector (Investment Managers), CNS carries a Roarable D- (43/100 RQD), trailing P/E of 24.5x, gross margin of —, and ROIC of 33.7%. By comparison, LAZ (Lazard Inc.) holds a C- grade (59/100 RQD, P/E 16.3x, ROIC 24.4%, cap $3.75B) and FHI (Federated Hermes Inc.) posts a B grade (74/100 RQD, P/E 10.7x, ROIC 39.8%, cap $4.37B). Among the 5-stock peer group, HTGC leads on earnings multiple (9.3x) while AAMI leads on capital efficiency (40.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CNS?

▼

Per CNS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001284812), Cohen & Steers Inc generated $497.7M in revenue (+2.8% YoY), $153.2M in net income, and -$126.4M in free cash flow against $876.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Financials with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $74.59 (+0.28%)🧬 Dilution Drag (+1.36% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-6.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CNS)Realized 20D OHLCV Swing Band: ±6.9%

Deterministic 5-Pillar Attribution (43/100 Composite)

🔍 WHY CNS SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution7/20 pts (-13 pt drag)

Dilution Drag (+1.36% YoY Shares) & executive Form 4 sales trim 13 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$68.86+4.6% Next Q

Q2 (-2Q)

Grade E$72.03-1.7% Next Q

Q3 (-1Q)

Grade D$70.79+5.1% Next Q

Current

Grade D-$74.38-6.7% Hist 90D α

Trajectory: E (35) → D- (43)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CNS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CNS currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Financials with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($73.86) and Max Pain ($78.10) forces dealer call-delta covering toward $90.89.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CNS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CNS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 43%NO 57%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

3.99% Total Yield

3.39% Cash ($2.52/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

41/100 • ELEVATED PAYOUT WATCH

FREE CASH FLOW PAYOUT RATIO

96% of FCF

8 consecutive years of payout growth

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (8.9% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $23,457

Est. Year-10 Shareholder Yield: $936/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.9K

Yr 1

$11.9K

Yr 2

$12.9K

Yr 3

$14.1K

Yr 4

$15.3K

Yr 5

$16.7K

Yr 6

$18.2K

Yr 7

$19.8K

Yr 8

$21.5K

Yr 9

$23.5K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CNS)

✓Walkthrough of CNS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CNS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +8.95%📐 HORIZONTAL RANGE

2026-11-03O $72.91H $74.38L $72.48C $74.38VOL 263.8K

RES: $84.85SUP: $63.59SMA50: $73.86SMA200: $72.04

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CNS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CNS Butterfly Map → + Track CNS →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

18.2%/yr Implied 5Y Growth

vs. +2.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CNS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CNS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CNS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CNS)

Financials Rank #840 of 1097 ⚔️ LAZ vs CNS Full Matrix →

1. Head-to-Head Financials Peer Comparison (CNS vs. LAZ, FHI, AAMI, HTGC)

Industry: Investment Managers (79 Tracked Issuers)

Across 1097 tracked Financials securities in the Roarable RQD universe, Cohen & Steers Inc (CNS) ranks #840 by composite RQD confidence (43/100, grade D-) and #320 by equity capitalization ($3.73B). Within this direct 5-issuer industry benchmark cohort, HTGC leads on earnings valuation at 9.3x trailing P/E, while AAMI leads on capital efficiency and profitability with 40.3% ROIC and — gross margin. FHI currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with CNS at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CNS ACTIVE Cohen & Steers Inc	D-	43/100	24.5x	—	33.7%	+2.62%	$3.73B	Benchmark Subject
LAZ Lazard Inc.	C-	59/100	16.3x	—	24.4%	+2.11%	$3.75B	/laz-vs-cns →
FHI Federated Hermes Inc.	B	74/100	10.7x	—	39.8%	+6.98%	$4.37B	/fhi-vs-cns →
AAMI Acadian Asset Management Inc.	D	50/100	40.5x	—	40.3%	-1.57%	$3.16B	/aami-vs-cns →
HTGC Hercules Capital Inc.	D-	42/100	9.3x	—	15.3%	-0.36%	$3.14B	/htgc-vs-cns →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001284812 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cohen & Steers Inc (CNS) reported GAAP revenue of $497.7M (+2.8% vs. FY2024 revenue of $484.1M , and +8.1% cumulative change since FY2023) , GAAP net income of $153.2M, operating cash flow of -$120.4M, and free cash flow of -$126.4M (-248.7% YoY). On the balance sheet, CNS closed FY2025 with $876.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$497.7M	$153.2M	-$120.4M	-$126.4M	$876.7M	—
FY2024 (FY)	2024-12-31	$484.1M	$151.3M	$96.7M	$85.0M	$812.4M	—
FY2023 (FY)	2023-12-31	$460.5M	$129.0M	$172.0M	$172.0M	—	—

3. CNS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CNS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CNS compare to LAZ and FHI in the Financials sector?

What are the biggest fundamental strengths and SEC risk factors for CNS?

Where is CNS trading relative to its 50-day, 200-day, and 52-week technical levels?

CNS last traded at $74.38 (+2.62% on volume of 374,936 shares), positioning the stock +0.70% above its 50-day simple moving average ($73.86) and +3.25% above its 200-day simple moving average ($72.04). Across its 52-week range of $58.39 to $86.56, CNS sits at the 56.8% percentile with a 14-day RSI of 51.9 (NEUTRAL RANGE) and an implied next-earnings move of ±6.9% ($69.25 to $79.51).

Direct Sub-Reports: CNS RQD Cockpit CNS 12M Forecast CNS Earnings & Move CNS Dividends & DRIP CNS Insiders & 13F CNS Whale Options CNS Profit Sankey CNS News & Why

ROARABLE RATING BRIEF • RQD 43/100 (D-) ✓ SEC XBRL & RQD VERIFIED

CNS — Cohen & Steers Inc: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Cohen & Steers Inc (CNS) earns a live Roarable RQD composite score of 43/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $74.38 (+2.62% 1D, market capitalization $3.73B).

Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of 33.7%, gross margin of —, operating margin of —, and free cash flow yield of -3.37%.
Whale 13F & Options Flow (9/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Cohen & Steers Inc (CNS) is a NYSE-listed issuer classified in the Financials sector and the Investment Managers industry..

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Cohen & Steers Inc (CNS) reported $497.7M in annual revenue (up from $484.1M in FY2024, +2.8% YoY) and $153.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($460.5M revenue, $129.0M net income) through FY2025, CNS scaled operating cash flow to -$120.4M and free cash flow to -$126.4M, backed by $876.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 43/100): Established market leader in Financials with deep daily trading liquidity. Free cash flow yield of -3.37% and institutional whale pillar of 9/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $58.39 – $86.56 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 24.5x trailing P/E and 19.7x EV/EBITDA against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Sector correlations beyond the Financials/Investment Managers classification are — The news wire does indicate that assets under management and yield-curve movements are the relevant second-order drivers: AUM declines reduce fee-based revenue, and yield-curve shifts are cited as a sensitivity. Investors should watch whether the Q3 revenue beat holds against the reported AUM decline, since a revenue beat alongside falling AUM would imply the beat is not sustained by asset growth.

Key Question #1: Can CNS sustain or expand its — operating margin and 33.7% ROIC against Investment Managers peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $497.7M and free cash flow of -$126.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is CNS's 22.8x forward P/E multiple to Financials capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CNS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cohen & Steers Inc (CNS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CNS Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 21h ago

Cohen & Steers' Assets Under Management Decline in September

Yahoo Finance report covering Cohen & Steers Inc (CNS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST GuruFocus • 1d ago

Cohen & Steers Inc (CNS) Shares Surge 5.3% -- What GF Score of 8

GuruFocus report covering Cohen & Steers Inc (CNS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 1d ago

Cohen & Steers’s (NYSE:CNS) Q3 2026: Beats On Revenue

TradingView report covering Cohen & Steers Inc (CNS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Cohen & Steers: Not Great With Upwards Yield Curve Movements (NYSE:CNS)

Seeking Alpha report covering Cohen & Steers Inc (CNS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Investing.com South Africa • 1d ago

Cohen & Steers stock leaps over 5% on strong inflows despite Q3 miss By Investing.com

Investing.com South Africa report covering Cohen & Steers Inc (CNS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Cohen & Steers, Inc. 2026 Q3 - Results - Earnings Call Presentation (NYSE:CNS) 2026-10-17

Seeking Alpha report covering Cohen & Steers Inc (CNS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Cohen & Steers, Inc. Declares Quarterly Dividend

TradingView report covering Cohen & Steers Inc (CNS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST SeekingAlpha • 3d ago

Dividend Champion, Contender, And Challenger Highlights: Week November 1

Get a weekly dividend summary for Champions, Contenders, and Challengers.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CNS Bull vs. Bear Conversation Board — What's Your Call at $74.38?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CNS 🐻 33% BEARISH CONVICTION

DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $84.08 (+16.0%)

📌 Pinned Debate

Reported Q3 2026 revenue beat and a 5.3% share surge suggest near-term market enthusiasm, with ROIC of 33.7% signaling high capital eff

Picked up a starter position in CNS in my $100K Virtual Cash book at $72.48. Reported Q3 2026 revenue beat and a 5.3% share surge suggest near-term market enthusiasm, with ROIC of 33.7% signaling high capital efficiency.. Trading inside a $58.39–$86.56 52-week range with -3.37% FCF yield gives solid downside support if Investment Managers multiples expand this quarter.

SectorRotator 🐂 BULL

@DeltaGamma_99 Agree on the RQD 43/100 quality, though with 1.0 beta I'm scaling in with half-size at $72.48 and keeping dry powder in case we test $67.41.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $57.26 (-21.0%)

Spot @ $72.48

Negative FY 2025 FCF of -$126.4M, a Piotroski F-Score of 2/9, and a 0% reported operating margin signal weak cash conversion and fundam

Negative FY 2025 FCF of -$126.4M, a Piotroski F-Score of 2/9, and a 0% reported operating margin signal weak cash conversion and fundamental quality.. Look at the math on CNS: paying 24.5x trailing P/E for 33.7% ROIC and 0.0% operating margins leaves zero margin of safety if Investment Managers demand softens. I'd wait for a retest of $63.78 before getting long.